Familial systemic scleroderma (scleroderma that runs in families)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study enrolls adults diagnosed with systemic scleroderma and at least one first-degree relative who meets the same criteria. Participants will have clinical characterization and biological samples collected to compare familial cases and search for molecular signatures, autoantibodies, or capillaroscopic changes linked to disease course. Inclusion uses VEDOSS criteria (Raynaud's phenomenon plus another supporting feature) and accepts limited, diffuse, sine, and overlap forms of systemic scleroderma. No experimental treatments are given; data and samples will be analyzed to identify markers and potential pathophysiological targets for future therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult subjects (≥ 18 years of age)
* Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities
* At least one first-degree relative with systemic scleroderma meeting the same criteria

Exclusion Criteria:

\- Subject who has expressed opposition to participating in the study

Where it's running

• Service de Médecine interne et Immunologie clinique - CHU de Strasbourg - France
  Strasbourg, France Recruiting

Study contacts

• Study coordinator: Aurélien GUFFROY, MD
• Email: aurelien.guffroy@chru-strasbourg.fr
• Phone: 33 3 69 5512 23

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies

  Researchers are testing to see how autoreactive B cells behave in people with autoimmune diseases or immune deficiencies to better understand how these cells may contribute to disease.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07251179

• SFDI imaging to measure skin fibrosis in diffuse cutaneous scleroderma

  This study tries SFDI, a painless light-based imaging method, to measure skin thickening in people with early diffuse cutaneous scleroderma.

  Recruiting Boston University · Boston, Massachusetts · NCT07090226

• Using nivolumab to treat patients with autoimmune disorders and advanced cancer

  This study is testing if nivolumab can safely help people with autoimmune disorders who also have advanced cancer by looking at how well it works and what side effects it might cause.

  Recruiting at 40 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 51 other locations · NCT03816345

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.